Carboplatin
- Atc Codes:L01XA02
- CAS Codes:41575-94-4
- PHARMGKB ID:41575-94-4
Table of contents
- Brand Names
- Drug Combinations
- Chemistry
- Pharmacologic Category
- Mechanism of Action
- Therapeutic Use
- Unlabeled Use
- Pregnancy and Lactation Implications
- Contraindications
- Warnings and Precautions
- Adverse Reactions
- Toxicological Effects
- Caution and personalized dose adjustment in patients with the following genotypes
- Other genes that may be involved
- Drug Interactions
- Nutrition/Nutraceutical Interactions
- Dosage
- Pharmacokinetics and Pharmacodynamics
- Special Considerations
Brand Names
Europe
Austria: Carboplatin; Belgium: Carboplatine, Carboplatinum, Carbosin; Bulgaria: Carboplatin; Cyprus: Carboplatin; Czech Republic: Carbomedac, Carboplatin, Cycloplatin; Denmark: Carboplatin; Estonia: Carboplatin; Finland: Carboplatin, Carbosin; France: Carboplatine; Germany: Axicarb, Carbo-cell, Carbomedac, Carboplat, Carboplatin, Carbox, Eurocarboplatin, Haemato-Carb, Neocarbo, Onkoplatin, Ribocarbo-L, Zytax; Greece: Carboplan, Carboplatin, Carbosin, Megaplatin, Paraplatin, Vadeplatin; Hungary: Carbomedac, Carboplatin, Cycloplatin, Paraplatin; Ireland: Carboplatin; Italy: Carboplatino, Paraplatin; Latvia: Carboplatin, Cytocarb; Lithuania: Carboplatin, Paraplatin; Luxembourg: Carboplatin, Carboplatinum, Paraplatin; Malta: Carboplatin; Netherlands: Carboplatin, Carboplatine, Carbosin; Poland: Carboplatin, Cycloplatin; Portugal: Carbomedac, Carboplatina, Novoplatinum; Romania: Carboplatin; Slovakia: Carbomedac, Carboplatin, Cycloplatin; Slovenia: Carboplatin, Carbosin, Paraplatin; Spain: Carboplatino, Paraplatin; Sweden: Carboplatin; UK: Carboplatin.
North America
Canada: Carboplatin; USA: Carboplatin, Paraplatin.
Latin America
Argentina: Carbokebir, Carboplat, Carboplatino, Carboxtie, Omilipis; Brazil: Biocarbo, B-Platín, Carboplatina, Oncoplatín, Paraplatín, Platamine CS, Tecnocarb, Vancel; Mexico: Bagotanillo, Blastocarb Ru, Boplatex, Carboplat, Kemocarb, Paraplatin.
Asia
Japan: Carbomerck, Carboplatin, Paraplatin.
Drug combinations
Carboplatin, Docetaxel, and Trastuzumab
Chemistry
Carboplatin: C~6~H~12~N~2~O~4~Pt. Mw: 371.25. (1) SP-4-2; (2) cis-Diammine(1,1-cyclobutanedicarboxylato)platinum. CAS-41575-94-4 (1983).
Pharmacologic Category
Other Antineoplastic Agents; Platinum Compounds. (ATC-Code: L01XA02).
Mechanism of action
Carboplatin is an alkylating agent which covalently binds to DNA. Possible cross-linking and interference with the function of DNA.
Therapeutic use
Treatment of ovarian cancer.
Pregnancy and lactiation implications
Pregnancy should be avoided during or for one month following therapy. May cause severe fetal defects. Contraindicated during lactation.
Unlabeled use
Lung cancer, head and neck cancer, endometrial cancer, esophageal cancer, bladder cancer, breast cancer, cervical cancer, CNS tumors, germ cell tumors, osteogenic sarcoma, and high-dose therapy with stem cell/bone marrow support.
Contraindications
Hypersensitivity to carboplatin, cisplatin, any component, other platinum-containing compounds, or mannitol. Severe bone marrow suppression or excessive bleeding. Pregnancy. Breast-feeding.
Warnings and precautions
Increased risk of allergic reactions in patients previously exposed to platinum therapy. Bone marrow suppression, which may be severe, is dose-related. Anemia is cumulative. High doses have resulted in severe abnormalities of liver function tests. Loss of vision (reversible) reported with higher than recommended doses. Vomiting may occur (dose-related). Use with caution in renal impairment. There is an increased incidence of peripheral neuropathy in patients who have previously received cisplatin, and patients >65 years of age. When administered as sequential infusions, taxane derivatives (docetaxel, paclitaxel) should be administered before the platinum derivatives (carboplatin, cisplatin), to limit myelosuppression and to enhance efficacy. Clinically significant hearing loss reported to occur in pediatric patients when therapy was administered at higher than recommended doses in combination with other ototoxic agents.